Cytochrome P450 isozymes involved in lisofylline metabolism to pentoxifylline in human liver microsomes

Drug Metabolism and Disposition

Volumn 25, Issue 12, 1997, Pages 1354-1358

  Lee, Sun H ^a   Slattery, John T ^b  

^a LG Chemical Ltd   (South Korea)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOTRIAZOLE DERIVATIVE; CYTOCHROME P450; LISOFYLLINE; OCTAMYLAMINE; PENTOXIFYLLINE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACULOVIRUS; CATALYSIS; DATA BASE; DNA DETERMINATION; HEART PERFUSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMITTENT CLAUDICATION; LIVER MICROSOME; PRIORITY JOURNAL; VISCOSITY;

CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; ENZYME INHIBITORS; HUMANS; ISOENZYMES; KINETICS; MICROSOMES, LIVER; PENTOXIFYLLINE; SUBSTRATE SPECIFICITY;

EID: 0031435602     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. J. W. Singer, A. List, D. Federighi, T. Michnick, and S. Bursten: Serum hydroperoxy and hydroxyoctadecadienoic acids (HPODE and HODE) increase in response to total body irradiation and are suppressed by lysofylline in allogenic BMT patients. Blood, in press.
2. K. Waxman, K. Daughters, S. Aswani, and G. Rice. Lysofylline decreases white cell adhesiveness and improves survial after experimental hemorrhagic shock. Crit. Care Med. 24, 1724-1728 (1996).
3. E. Abraham, S. Bursten, R. Shenkar, J. Allbee, R. Tuder, P. Woodson, D. M. Guidot, G. Rice, J. W. Singer, and J. E. Repine: Phosphatidic acid signaling mediates lung cytokine expression and lung inflammatory injury after hemorrhage in mice. J. Exp. Med. 181, 569-575 (1995).
4. E. Ernst: Pentoxifylline for intermittent claudication: a critical review. Angiology 45, 339-345 (1994).
5. J. A. Bianco, F. R. Appelbaum, J. Nemunaitis, J. Almgren, F. Andrews, P. Kettner, A. Shields, and J. W. Singer: Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood 78, 1205-1211 (1991).
6. J. A. Thompson, J. A. Bianco, M. C. Benyunes, M. A. Neubauer, J. T. Slattery, and A. Feber: Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma. Cancer Res. 54, 3436-3441 (1994).
7. B. J. Dezube: Pentoxifylline for the treatment of infection with human immunodeficiency virus. Clin. Infect. Dis. 18, 285-287 (1994).
8. D. Landman, A. Sarai, and S. S. Sathe: Use of pentoxifylline therapy for patients with AIDS-related wasting: pilot study. Clin. Infect. Dis. 18, 97-99 (1994).
9. R. K. Campbell: Clinical update on pentoxifylline therapy for diabetes-induced peripheral vascular disease. Ann. Pharmacother. 27, 1099-1105 (1993).
10. J. Tesarik and C. Mendoza: Sperm treatment with pentoxifylline improves the fertilizing ability in patients with acrosome reaction insufficiency. Fertil. Steril. 60, 141-148 (1993).
11. H. Tournaye, A. C. Van Steirteghem, and P. Devroey: Pentoxifylline in idiopathic male-factor infertility: a review of its therapeutic efficacy after oral administration. Hum. Reprod. 9, 996-1000 (1994).
12. S. Sanchez, L. Albornoz, J. C. Bandi, S. Gerona, and R. Mastai: Pentoxifylline, a drug with Theological effects, decreases portal pressure in an experimental model of cirrhosis. Eur. J. Gastroenterol. Hepatol. 9, 27-31 (1997).
13. M. Carrier, G. B. Pelletier, M. White, D. Bois, and L. C. Delletier: Effect of pentoxifylline on renal toxicity of cyclosporine: Results of a clinical trial after heart transplantation. J. Heart Lung Transplant. 15, 1179-1183 (1996).
14. H. J. Von Hinze, G. Bedebem, and A. Söde: Struktur der ausscheidung sprodukte des 3.7-dimethyl-1-(5-oxo-hexyl)-xanthines (BL 191) beim menschen. Arzneimittelforschung 22, 1144-1151 (1972).
15. 14C pentoxifylline in healthy volunteers. Arzneimittelforschung 39, 512-517 (1989).
16. A. Mancinelli, S. Pace, A. Marzo, and E. A. Martelli: Determination of pentoxifylline and its metabolites in human plasma by high performance liquid chromatography with solid-phase extraction. J. Chromatogr. 575, 101-107 (1992).
17. J. A. Lillibridge, T. F. Kalhorn, and J. T. Slattery: Metabolism of lisofylline and pentoxifylline in human liver microsomes and cytosol. Drug Metab. Dispos. 24, 1174-1179 (1996).
18. D. Sesardic, A. R. Boobis, B. P. Murray, S. Murray, J. Segura, R. de la Torre, and D. S. Davies: Furafylline is a potent and selective inhibitor of cytochrome P450 1A1 in man. Br. J. Clin. Pharmacol. 29, 651-663 (1990).
19. K. L. Kunze and W. F. Trager: Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem. Res. Toxicol. 6, 649-656 (1993).
20. D. J. Newton, R. W. Wang, and A. Y. H. Lu: Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos. 23, 154-158 (1995).
21. J. S. Miles, A. W. McLaren, L. M. Forrester, M. J. Glancey, M. A. Lang, and C. R. Wolf: Identification of the human liver cytochrome P450 responsible for coumarin 7-hydroxylase activity. Biochem. J. 267, 365-371 (1990).
22. G. F. Reidy, I. Mehta, and M. Murray: Inhibition of oxidative drug metabolism by orphenadrine: in vitro evidence for isozyme-specific complexation of cytochrome P-450 and inhibition kinetics. Mol. Pharmacol. 35, 736-743 (1989).
23. M. V. Relling, T. Aoyama, F. J. Gonzalez, and U. A. Meyer: Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP 2C subfamily. J. Pharmacol. Exp. Ther. 252, 442-447 (1990).
24. C. J. Doecke, M. E. Veronese, S. M. Pond, J. O. Miners, D. J. Birkett, L. N. Sansom, and M. E. McManus: Relationship between phenytoin and tolbutamide hydroxylation in human liver microsomes. Br. J. Clin. Pharmacol. 31, 125-130 (1991).
25. M. E. Veronese, P. I. MacKenzie, C. J. Doecke, M. E. McManus, J. O. Miners, and D. J. Birkett: Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P450 2C9. Biochem. Biophys. Res. Commun. 175, 1112-1118 (1991).
26. J. R. Halpert, F. P. Guengerich, J. R. Bend, and M. A. Correia: Selective inhibitors of cytochromes P450. Toxicol. Appl. Pharmacol. 125, 163-175 (1994).
27. S. A. Wrighton, J. C. Stevens, G. W. Becker, and M. VandenBraden: Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and. S-mephenytoin 4′hydroxylation. Arch. Biochem. Biophys. 306, 240-245 (1993).
28. J. A. Goldstein, M. B. Faletto, M. Rankes-Sparks, T. Sullivan, J. L. Raucy, S. Kitareewan, J. M. Lasker, and B. I. Ghanayem: Evidence that P450 2C19 is the major (S)-mephenytoin 4′ hydroxylase in humans. Biochem. 33, 1743-1752 (1994).
29. T. Inaba, M. Jurima, W. A. Mahon, and W. Kalow: In vitro inhibition studies of two isozymes of human liver cytochrome P450; Mephenytoin P-hydroxylase and spartein monooxygenase. Drug. Metab. Dispos. 13, 443-448 (1985).
30. F. P. Guengerich, D. Muller-Enoch, and I. A. Blair: Oxidation of quinidine by human liver microsomal P450. Mol. Pharmacol. 30, 287-295 (1986).
31. F. P. Guengerich, D. M. Kim, and M. Iwasaki: Role of human cytochrome P450 IIE1 in the oxidation of several low molecular weight cancer suspects. Chem. Res. Toxicol. 4, 168-179 (1991).
32. H. Yamazaki, Y. Inui, C-H. Yun, F. P. Guengerich, and T. Shimada: Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkyl amines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 13, 1789-1794 (1992).
33. T. K. Chang, F. J. Gonzalez, and D. J. Waxman: Evaluation of triacetyloleandomycin, α-naphthoflavone, and diethyldithiocarbamate as selective chemical probe for inhibition of human cytochrome P450. Arch. Biochem. Biophys. 311, 437-442 (1994).
34. M. J. Namkung, H. L. Yang, J. E. Hulla, and M. R. Juchau: On the substrate specificities of cytochrome P450 IIIA1. Mol. Pharmacol. 34, 628-637 (1988).
35. M. Bourrie, V. Meunier, Y. Berger, and G. Fabre: Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J. Pharmacol. Exp. Ther. 277, 321-332 (1996).
36. K. L. Kunze, L. C. Wienkers, K. E. Thummel, and W. F. Trager: Warfarinfluconazole I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: In vitro studies. Drug Metab. Dispos. 24, 414-421 (1996).
37. K. E. Thummel, E. D. Kharasch, T. Podoll, and K. L. Kunze: Human liver microsomal enflurane defluorination catalyzed by cytochrome P-450 2E1. Drug Metab. Dispos. 21, 350-357 (1993).